Marked improvement in bone mineral density (BMD) for patients (pts) with monoclonal gammopathy of undetermined significance (MGUS) using zoledronic acid (ZOL)
James R. Berenson(Oncotherapeutics (United States)), R. Swift, Olcay Batuman(SUNY Downstate Health Sciences University), Herbert L. Duvivier, Ori Yellin, Youram Nassir, Stephen Heung‐Sang Wong(Seattle Children's Hospital), M. Moezi, Marshall S. Flam, Ralph V. Boccia(Center for Cancer and Blood Disorders), Donald Woytowitz
Cited by 2
Related Papers
Carbohydrates for training and competition
|Journal of Sports Sciences|2011|953
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Assessment of thymic output in adults after haematopoietic stemcell transplantation and prediction of T-cell reconstitution
|The Lancet|2000|579
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425